Skip to main content

ASCIA News

  • Updated ASCIA Adrenaline Device PBS Authority Form
    ASCIA recommends the use of adrenaline (epinephrine) as the first line emergency/first aid treatment for severe allergic reactions (anaphylaxis) using either of the following two brands of adrenaline injector devices, EpiPen® or Anapen®, which are both available in...
  • ASCIA 2024 Conference registration is still open
    Registration is still open for the ASCIA 2024 Conference at https://ascia2024.com/registration To date there are 455 registered delegates (80% in person), a sold out exhibition and more than 150 abstracts have been received for posters and clinical grand rounds. Authors will...
  • Updates to Australian medicine labelling rules to support medicine safety
    The Therapeutic Goods Administration (TGA) public consultation is now open on Updates to Australian medicine labelling rules to support medicine safety to seek feedback to make sure proposed changes to labelling rules support the safe use of medicines. The TGA is proposing...
  • Allergic reactions to Andrographis paniculata
    The ASCIA website article on Adverse Reactions to Complementary and Alternative Medicine has been updated to include information about Andrographis paniculata. This herb is commonly used in Indian and Chinese medicine and is known as the 'king of bitters'. Since 2019, the...
  • Saphnelo (anifrolumab) listed on the PBS for patients with severe SLE - 1 July 2024
    Saphnelo® (anifrolumab) has been listed on the PBS for patients with severe SLE with high disease activity despite standard of care from Monday 1st July 2024. ​The listing details have been published on the PBS website on 1 July 2024 with the below initial treatment...
  • Product Update - Anapen® Adrenaline Injector Devices
    Arrotex Pharmaceuticals has advised that the sale and distribution of Anapen® Junior 150 and Anapen® 300 used for the emergency treatment of anaphylaxis are to cease in Australia: Anapen® 300 will be available until end July 2024. Anapen® Junior 150 will be available until...
  • ASI Clinical Translation School 2024
    The second ASI Clinical Translation School will be held at Q Station in Manly, Sydney from Wednesday 18th to Friday 20th September 2024. This in-person intensive 2-day School will host an expert line-up of clinical translation speakers, and an engaged network of...
  • Arexvy® RSV Vaccine
    ASCIA has submitted a letter of support for the Arexvy® Respiratory Syncytial Virus (RSV) Vaccine application for new National Immunisation Program (NIP) listing (lodged 29 May 2024) which is available at https://www.allergy.org.au/ascia-submissions  Respiratory Syncytial Virus (RSV) recombinant subunit vaccine...
ASCIA Member Login

Site last updated: 11 Jun 2024
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...